Bioxcel therapeutics, inc. (BTAI)
CashFlow / Yearly
Dec'19Dec'18Dec'17
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss

-32,968

-19,270

-4,539

Reconciliation of net loss to net cash used in operating activities
Depreciation and amortization

156

17

1

Stock-based compensation expense

3,142

3,082

1,606

Changes in operating assets and liabilities:
Prepaid expenses and other assets

1,190

539

1

Accounts payable, accrued expenses and other

3,580

3,201

737

Net cash used in operating activities

-27,280

-13,509

-2,196

CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of equipment and leasehold improvements

870

340

-

Net cash used in investing activities

-870

-340

-

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock, net of issuance costs

17,810

56,513

2,061

Exercise of options

22

7

-

Net Parent Investment

-

-

214

Deferred offering expense

-

-

70

Payable to Parent for services

-

-67

67

Due to Parent

179

-555

440

Note Payable — Parent

-

-371

371

Net cash provided by financing activities

18,011

55,527

3,083

Net (decrease) increase in cash and cash equivalents

-10,139

41,678

887

Supplemental cash flow information:
Interest paid

62

1

-

Supplemental disclosure of non-cash Operating, Investing and Financing Activities:
Deferred issuance costs, unpaid as of December 31, 2017

-

-

391

Deferred issuance costs reclassified to additional paid-in-capital upon completion of initial public offering

-

461

-

Right-of-use asset obtained in exchange for new operating lease liability

1,308

-

-

Reclassification of net Parent Investment in the Company to accumulated deficit.

-

-

440